Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

CLLS

Cellectis ADR

Apr 10 • 04:00PM ET

3.59

+0.09 2.57 %

Healthcare • Biotechnology • France • NASD

Peers: CRSP NTLA SGMO BLUE EDIT QURE RCKT CYTK ADAP ARCT

| Held by: IBB

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.68	Insider Own	3.93%	Shs Outstand	100.34M	Perf Week	5.28%
Market Cap	259.66M	Forward P/E	-	EPS next Y	-0.85	Insider Trans	0.00%	Shs Float	69.48M	Perf Month	-5.53%
Enterprise Value	170.90M	PEG	-	EPS next Q	-0.26	Inst Own	14.62%	Short Float	0.52%	Perf Quarter	-19.87%
Income	-67.91M	P/S	3.56	EPS this Y	-63.11%	Inst Trans	3.48%	Short Ratio	8.50	Perf Half Y	-16.51%
Sales	73.01M	P/B	4.75	EPS next Y	22.22%	ROA	-18.76%	Short Interest	0.36M	Perf YTD	-25.83%
Book/sh	0.76	P/C	1.24	EPS next 5Y	-19.47%	ROE	-65.63%	52W High	5.48 -34.48%	Perf Year	191.87%
Cash/sh	2.88	P/FCF	-	EPS past 3/5Y	33.81% 18.84%	ROIC	-38.23%	52W Low	1.20 199.17%	Perf 3Y	83.16%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	56.25% -0.34%	Gross Margin	72.47%	Volatility	4.90% 6.04%	Perf 5Y	-81.98%
Dividend TTM	-	EV/Sales	2.34	EPS Y/Y TTM	-109.46%	Oper. Margin	-55.52%	ATR (14)	0.22	Perf 10Y	-87.56%
Dividend Ex-Date	-	Quick Ratio	1.62	Sales Y/Y TTM	76.18%	Profit Margin	-93.01%	RSI (14)	53.93	Recom	1.43
Dividend Gr. 3/5Y	- -	Current Ratio	1.62	EPS Q/Q	-421.20%	SMA20	6.45%	Beta	2.98	Target Price	7.36
Payout	-	Debt/Eq	1.58	Sales Q/Q	-17.71%	SMA50	-0.55%	Rel Volume	0.25	Prev Close	3.50
Employees	229	LT Debt/Eq	1.34	Earnings	Mar 19 AMC	SMA200	2.98%	Avg Volume	42.17K	Price	3.59
IPO	Mar 25, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	-27.89% -9.16%	Trades		Volume	10,567	Change	2.57%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-17-26	Resumed	Jefferies	Buy	$7
Mar-17-23	Initiated	Bryan Garnier	Buy	$6
May-18-22	Upgrade	Robert W. Baird	Neutral → Outperform	$10
Jan-06-22	Downgrade	Wells Fargo	Overweight → Equal Weight	$39 → $16
Nov-30-21	Initiated	JMP Securities	Mkt Outperform	$20
Nov-08-21	Downgrade	William Blair	Outperform → Mkt Perform
Oct-08-21	Downgrade	Robert W. Baird	Outperform → Neutral	$39 → $10
Apr-28-21	Downgrade	Guggenheim	Buy → Neutral
Mar-16-21	Upgrade	Robert W. Baird	Neutral → Outperform	$23 → $39
Aug-19-20	Upgrade	Citigroup	Neutral → Buy	$15 → $32
May-12-20	Initiated	Robert W. Baird	Outperform	$20
Mar-06-20	Downgrade	Goldman	Neutral → Sell	$15 → $11
Oct-30-19	Resumed	Guggenheim	Buy	$28
Aug-09-19	Initiated	BTIG Research	Buy	$37
May-24-19	Resumed	Citigroup	Neutral	$22
Mar-14-19	Initiated	William Blair	Outperform
Dec-19-18	Initiated	Goldman	Neutral
Jul-16-18	Initiated	Barclays	Overweight	$50
Mar-16-18	Initiated	Guggenheim	Neutral
Sep-05-17	Reiterated	Wells Fargo	Outperform	$33 → $40

Show Previous Ratings

Apr-07-26 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire) +5.65%
Mar-20-26 03:00PM	Cellectis SA (CLLS) Q4 2025 Earnings Call Highlights: Promising Clinical Progress and Strategic ... (GuruFocus.com)
Mar-19-26 07:21PM	Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update (GlobeNewswire)
09:17AM	What To Expect From Cellectis SA (XPAR:ALCLS) Q4 2025 Earnings (GuruFocus.com)
Mar-12-26 04:30PM	Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026 (GlobeNewswire) -12.37%
03:33AM	Loading…
03:33AM	Poolbeg Pharma adds CAR-T therapy expert to scientific advisory board (Proactive)
Mar-04-26 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Feb-04-26 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Jan-08-26 04:30PM	Cellectis Announces 2026 Strategy and Catalysts (GlobeNewswire)
Jan-05-26 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire) -5.42%
Dec-15-25 04:51PM	Cellectis Announces Arbitral Decision in Dispute with Servier (GlobeNewswire) -15.24%
Dec-08-25 01:30AM	ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL (GlobeNewswire)
Dec-03-25 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Nov-19-25 06:18AM	Cellectis Publishes Nature Communications Article on a Non-Viral Gene Editing Process Enabling Efficient Gene Insertion in Hematopoietic Stem Cells (GlobeNewswire) +7.06%
Nov-07-25 04:30PM	Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) +11.29%
11:30AM	Loading…
11:30AM	Monthly information on share capital and company voting rights (GlobeNewswire)
Nov-03-25 09:15AM	Cellectis to Present a Development Update for eti-cel at ASH 2025 (GlobeNewswire) -5.22%
Oct-31-25 04:30PM	Cellectis to Report Third Quarter Financial Results on November 7, 2025 (GlobeNewswire)
Oct-16-25 03:19PM	Cellectis' R&D Day Highlights Lasme-cel's Potential to Address Significant Unmet Need for Patients with r/r B-ALL (GlobeNewswire) +9.98%
07:00AM	Cellectis Hosts R&D Day Today Showcasing Pipeline Progress and Long-Term Value Drivers (GlobeNewswire)
Oct-07-25 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire) +8.22% +12.57%
02:40AM	Cellectis to Present Data on Non-Viral Gene Therapy and TALE Base Editors at the ESGCT Annual Congress (GlobeNewswire)
Sep-03-25 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Aug-07-25 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Aug-04-25 04:30PM	Cellectis Reports Second Quarter 2025 Financial Results & Business Updates (GlobeNewswire) -16.23%
10:04AM	Earnings To Watch: Cellectis SA (CLLS) Reports Q2 2025 Result (GuruFocus.com)
Jul-28-25 04:30PM	Cellectis to Report Second Quarter 2025 Financial Results on August 4, 2025 (GlobeNewswire) +13.10%
Jul-04-25 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Jun-26-25 04:30PM	Cellectis Reports Results from Shareholders Meeting Held on June 26, 2025 (GlobeNewswire)
Jun-05-25 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
04:30PM	Loading…
May-21-25 04:30PM	Cellectis' Annual Shareholders General Meeting to be Held on June 26, 2025 (GlobeNewswire)
May-12-25 04:30PM	Cellectis Reports Financial Results for the First Quarter 2025 (GlobeNewswire) -6.62%
May-07-25 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
May-06-25 04:30PM	Cellectis to Report First Quarter Financial Results on May 12, 2025 (GlobeNewswire)
Apr-28-25 04:30PM	Cellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual Meeting (GlobeNewswire)
Apr-22-25 09:00AM	Cellectis Charts Course for 2025 With Boost From AstraZeneca Deal (MarketBeat)
Apr-21-25 05:02PM	Cellectis SA (CLLS) Q4 2024 Earnings Call Highlights: Strategic Collaborations and Financial ... (GuruFocus.com)
Apr-07-25 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire) +5.00%
Mar-13-25 06:07PM	Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update (GlobeNewswire)
Mar-07-25 04:30PM	Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025 (GlobeNewswire)
Mar-06-25 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Feb-24-25 01:30AM	Cellectis Presents 'Smart CAR T' Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025 (GlobeNewswire)
Feb-04-25 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Jan-28-25 08:00AM	Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer (GlobeNewswire)
Jan-08-25 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire) -8.10%
Jan-07-25 11:28AM	Do Options Traders Know Something About Cellectis (CLLS) Stock We Don't? (Zacks)
Dec-29-24 08:24AM	Analysts Predict 400% Upside Potential for This Penny Stock (GuruFocus.com)
Dec-10-24 04:30PM	Cellectis announces the drawdown of the third tranche of 5 million under the credit facility agreement entered with the European Investment Bank (EIB) (GlobeNewswire)
Dec-04-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Nov-06-24 04:38PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Nov-05-24 04:30PM	Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting (GlobeNewswire)
Nov-04-24 04:30PM	Cellectis Provides Business Updates and Financial Results for Third Quarter 2024 (GlobeNewswire)
07:14AM	What To Expect From Cellectis SA (CLLS) Q3 2024 Earnings (GuruFocus.com)
Oct-30-24 04:30PM	Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024 (GlobeNewswire)
Oct-23-24 06:29AM	Cellectis Presents New Gene-Editing Breakthroughs (TipRanks) +9.44%
Oct-22-24 02:00AM	Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress (GlobeNewswire)
Oct-02-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Sep-04-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Sep-03-24 04:30PM	Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety (GlobeNewswire) -5.83%
Aug-26-24 04:30PM	Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors (GlobeNewswire)
Aug-07-24 02:00AM	Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer (GlobeNewswire)
Aug-06-24 04:30PM	Cellectis Provides Financial Results for the Second Quarter 2024 (GlobeNewswire)
Aug-05-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Aug-02-24 09:53AM	Cellectis starts alemtuzumab revival with FDA orphan drug win in leukaemia (Pharmaceutical Technology)
Aug-01-24 04:30PM	FDA Grants Orphan Drug Designation to Cellectis' CLLS52 (alemtuzumab) For ALL Treatment (GlobeNewswire)
Jul-25-24 04:30PM	FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis' UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment (GlobeNewswire) +12.20%
Jul-10-24 09:35AM	Down -22.78% in 4 Weeks, Here's Why You Should You Buy the Dip in Cellectis (CLLS) (Zacks)
Jul-05-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Jun-28-24 04:30PM	Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024 (GlobeNewswire)
Jun-20-24 04:30PM	Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing (GlobeNewswire)
Jun-18-24 12:00PM	Cellectis (CLLS) Upgraded to Buy: Here's Why (Zacks) -5.84%
09:35AM	After Plunging -27.95% in 4 Weeks, Here's Why the Trend Might Reverse for Cellectis (CLLS) (Zacks)
Jun-12-24 04:30PM	Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications (GlobeNewswire)
Jun-05-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire) +6.23%
Jun-04-24 04:30PM	Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia (GlobeNewswire)
May-29-24 04:30PM	Cellectis' Annual Shareholders General Meeting to be Held on June 28, 2024 (GlobeNewswire)
May-28-24 08:52PM	CLLS Stock Earnings: Cellectis Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:30PM	Cellectis Reports Financial Results for First Quarter 2024 (GlobeNewswire)
May-27-24 04:30PM	Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024 (GlobeNewswire)
May-16-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
May-06-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire) +12.04% -7.46%
04:22AM	Cellectis Secures $140 Million Additional Equity Investment From AstraZeneca (MT Newswires)
02:00AM	Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca (GlobeNewswire)
May-03-24 06:10AM	Cellectis CFO Bing Wang Retires, Interim CFO Appointed (MT Newswires)
May-02-24 04:30PM	Cellectis Appoints Arthur Stril as Interim Chief Financial Officer (GlobeNewswire) +17.90%
Apr-29-24 10:53PM	CLLS Stock Earnings: Cellectis Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
04:46PM	Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023 (GlobeNewswire)
Apr-22-24 04:30PM	Cellectis Presents Novel TALEN Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs (GlobeNewswire)
Apr-10-24 04:30PM	Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs (GlobeNewswire)
Apr-08-24 04:30PM	Cellectis Announces Two Poster Presentations on Novel TALEN Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting (GlobeNewswire)
Apr-04-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Mar-04-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Feb-02-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Jan-16-24 04:30PM	Cellectis announces the drawdown of the second tranche of 15 million under the credit facility agreement entered with the European Investment Bank (EIB) (GlobeNewswire) -5.42%
Jan-08-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Dec-22-23 04:30PM	Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023 (GlobeNewswire)
Dec-01-23 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire) -5.59%
Nov-17-23 04:30PM	Cellectis' Shareholders Meeting to be Held on December 22, 2023 (GlobeNewswire) +11.83% +5.80%
Nov-15-23 02:30AM	Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca (GlobeNewswire) +9.38%
Nov-06-23 04:30PM	Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023 (GlobeNewswire) -13.41%

Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J. Sourdive and Andre Choulika on February 20, 1999 and is headquartered in Paris, France.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CLLS

Cellectis ADR

Upgrade your Finviz experience